These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23925295)

  • 1. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.
    Hanks BA; Holtzhausen A; Evans KS; Jamieson R; Gimpel P; Campbell OM; Hector-Greene M; Sun L; Tewari A; George A; Starr M; Nixon AB; Augustine C; Beasley G; Tyler DS; Osada T; Morse MA; Ling L; Lyerly HK; Blobe GC
    J Clin Invest; 2013 Sep; 123(9):3925-40. PubMed ID: 23925295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
    Holtzhausen A; Zhao F; Evans KS; Tsutsui M; Orabona C; Tyler DS; Hanks BA
    Cancer Immunol Res; 2015 Sep; 3(9):1082-95. PubMed ID: 26041736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
    Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
    J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms.
    Nishida J; Miyazono K; Ehata S
    Oncogene; 2018 Apr; 37(16):2197-2212. PubMed ID: 29391598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.
    Zheng X; Koropatnick J; Chen D; Velenosi T; Ling H; Zhang X; Jiang N; Navarro B; Ichim TE; Urquhart B; Min W
    Int J Cancer; 2013 Feb; 132(4):967-77. PubMed ID: 22870862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD83 inhibits acute rejection by up regulating TGF-β and IDO secretion in rat liver transplantation.
    Xiong L; Wang D; Lin S; Wang Y; Luo M; Gao L
    Transpl Immunol; 2021 Feb; 64():101351. PubMed ID: 33171217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDF15 Regulates Malat-1 Circular RNA and Inactivates NFκB Signaling Leading to Immune Tolerogenic DCs for Preventing Alloimmune Rejection in Heart Transplantation.
    Zhang Y; Zhang G; Liu Y; Chen R; Zhao D; McAlister V; Mele T; Liu K; Zheng X
    Front Immunol; 2018; 9():2407. PubMed ID: 30425709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions.
    Onodera T; Jang MH; Guo Z; Yamasaki M; Hirata T; Bai Z; Tsuji NM; Nagakubo D; Yoshie O; Sakaguchi S; Takikawa O; Miyasaka M
    J Immunol; 2009 Nov; 183(9):5608-14. PubMed ID: 19843945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of chimeric vaccine stimulation of indoleamine 2,3-dioxygenase biosynthesis in human dendritic cells is independent of TGF-β signaling.
    Esebanmen GE; Langridge WHR
    Cell Immunol; 2017 Sep; 319():43-52. PubMed ID: 28864263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.
    Criswell TL; Dumont N; Barnett JV; Arteaga CL
    Cancer Res; 2008 Sep; 68(18):7304-12. PubMed ID: 18794117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-β signaling.
    Ansa-Addo EA; Zhang Y; Yang Y; Hussey GS; Howley BV; Salem M; Riesenberg B; Sun S; Rockey DC; Karvar S; Howe PH; Liu B; Li Z
    J Clin Invest; 2017 Apr; 127(4):1321-1337. PubMed ID: 28287407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma.
    Cheng CW; Hsiao JR; Fan CC; Lo YK; Tzen CY; Wu LW; Fang WY; Cheng AJ; Chen CH; Chang IS; Jiang SS; Chang JY; Lee AY
    Mol Carcinog; 2016 May; 55(5):499-513. PubMed ID: 25728212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.
    Furudate S; Fujimura T; Kambayashi Y; Kakizaki A; Hidaka T; Aiba S
    Anticancer Res; 2017 Jul; 37(7):3461-3471. PubMed ID: 28668835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral probiotic promotes indoleamine 2,3-dioxygenase- and TGF-β-Producing plasmacytoid dendritic cells to initiate protection against type 1 diabetes.
    Nelson AS; Akgul A; Maddaloni M; Bhagyaraj E; Hoffman C; Pascual DW
    Immunol Lett; 2021 Nov; 239():12-19. PubMed ID: 34333043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy.
    Zhang M; Berndt BE; Chen JJ; Kao JY
    J Immunol; 2008 Sep; 181(5):3690-7. PubMed ID: 18714045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.
    Cauwels A; Van Lint S; Paul F; Garcin G; De Koker S; Van Parys A; Wueest T; Gerlo S; Van der Heyden J; Bordat Y; Catteeuw D; Rogge E; Verhee A; Vandekerckhove B; Kley N; Uzé G; Tavernier J
    Cancer Res; 2018 Jan; 78(2):463-474. PubMed ID: 29187401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.
    Llopiz D; Dotor J; Casares N; Bezunartea J; Díaz-Valdés N; Ruiz M; Aranda F; Berraondo P; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
    Int J Cancer; 2009 Dec; 125(11):2614-23. PubMed ID: 19530254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment.
    Xu Z; Wang Y; Zhang L; Huang L
    ACS Nano; 2014 Apr; 8(4):3636-45. PubMed ID: 24580381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
    Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
    Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.